BRIEF published on 12/16/2025 at 21:23, 8 months 6 days ago ABIONYX Pharma Announces a Capital Increase Fundraising Capital Increase Biopharmaceutical ABIONYX Pharma Sepsis
BRIEF published on 12/16/2025 at 21:23, 8 months 6 days ago ABIONYX Pharma Announces €1.8 Million Capital Increase Capital Increase Subscription Rights Euronext Listing ABIONYX Pharma Financial Visibility
PRESS RELEASE published on 12/16/2025 at 21:18, 8 months 6 days ago Inside Information / Other news releases ABIONYX Pharma launches €1.8m capital increase with removal of preferential subscription rights, subscription price at 3.10 euros for new shares, extending financial visibility until 2026 Capital Increase Biopharma Preferential Subscription Rights ABIONYX Pharma Financial Visibility
BRIEF published on 12/05/2025 at 18:05, 8 months 18 days ago ABIONYX Reports Monthly Voting Rights and Share Data Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
PRESS RELEASE published on 12/05/2025 at 18:00, 8 months 18 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 8 months 28 days ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 8 months 28 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 9 months 11 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 10 months 2 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 10 months 2 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
Published on 08/22/2026 at 05:50, 1 day 14 hours ago Battery X Metals Provides Board of Directors Update
Published on 08/22/2026 at 04:55, 1 day 15 hours ago Vanta Announces Closing of First Tranche of Private Placement and Board of Directors Update
Published on 08/22/2026 at 00:30, 1 day 19 hours ago BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Published on 08/21/2026 at 23:00, 1 day 21 hours ago Tintina Mines Announces Voting Results from its Annual General and Special Meeting of Shareholders
Published on 08/21/2026 at 23:00, 1 day 21 hours ago Silver Storm Announces $7.5 Million Non-Brokered Private Placement with Eric Sprott
Published on 08/21/2026 at 19:36, 2 days ago EQS-Adhoc: KAP AG ANNOUNCES CHANGE IN SHAREHOLDER STRUCTURE
Published on 08/21/2026 at 19:11, 2 days 1 hour ago EQS-Adhoc: Marley Spoon Group SE: Discussions with Misfits Market as permanent US fulfillment agent
Published on 08/21/2026 at 18:14, 2 days 1 hour ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/21/2026 at 17:27, 2 days 2 hours ago EQS-Adhoc: PSI Adjusts Its Forecast for Fiscal Year 2026 in Light of Economic Uncertainties in Europe
Published on 08/21/2026 at 16:30, 2 days 3 hours ago BL Networks (BLNWX) Details Major Global Infrastructure Expansion and Upgrades
Published on 08/18/2026 at 11:15, 5 days 8 hours ago GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 08:33, 6 days 11 hours ago Covivio - Information on Treasury shares transactions between August 10th, 2026 and August 11th, 2026
